CiVi Biopharma
Chevy Chase
About CiVi Biopharma
CiVi Biopharma is a clinical stage research and development biotechnology company whose mission is to create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company has multiple assets in various stages of development including Intravenous Iloprost in Phase 3 trials for treatment of Systemic Sclerosis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $89.0M
- Last round: Series Unknown (May 2018)
- Website: civibio.com
- Phone: 301-968-2390
Industries & Categories
Biotechnology, Clinical Trials, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/civi-biopharma-153104 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.